drug_type
RELEVANT_DRUG
intervention_type
Cellular and gene therapy (autologous CAR T-cell; ATMP/GTMP)
drug_description
Autologous anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy. Patient T cells are genetically modified to express a CD19-targeted CAR; upon CD19 engagement, CAR signaling activates and expands T cells to mediate cytotoxic killing and cytokine release, depleting CD19+ B cells and clearing tumors. Administered as a single IV infusion at 0.2–2.0 × 10^6 CAR T cells/kg. Indications include B-ALL, large B-cell lymphoma (DLBCL/PMBCL/transformed FL), and mantle cell lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor. Upon binding CD19 on B-lineage tumor cells, CAR signaling activates and expands the T cells, inducing cytotoxic granule release and cytokine-mediated killing that depletes CD19+ B cells and clears tumors.
drug_name
FCTX-CL19-1 (Tarcidomgen Kimleucel)
nct_id_drug_ref
NCT06593145